drugset / Trial / NCT04947423
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Phase 3
Completed
140 enrolled
Repurposed Therapeutics, Inc.
Defender Pharmaceuticals, Inc. · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
Timeline
- Start
- 2021-06-14
- Primary completion
- 2021-08-12
- Completion
- 2021-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Scopolamine | Unknown | 0.2 mg | Intranasal |